Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2021

View Archived Issues

Second interim analysis data from phase IIa study of vilobelimab in pyoderma gangrenosum

Resveratrol-triggered switches maximize cancer immunotherapy, reduce toxicity

Final topline data presented from DeCidE1 study of MVP-S in ovarian cancer

New PSMB8 inhibitors divulged by Shouyao Holdings

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents BCR-ABL inhibitors

New MAP4K1 inhibitors identified at Blueprint Medicines

Mindset presents preclinical data for next-generation psychedelic drug families

Beta Pharma synthesizes new FGFR inhibitors

aTyr expands its research collaboration with Ohio State University

Positive interim data presented from phase I study of FTX-6058

Anti-PRNP monoclonal antibody decreases tau pathology in mouse Alzheimer's disease model

Kaleido and COPD Foundation collaborate to advance development of KB-109

Skye completes IND-enabling genotoxicity studies for THCVHS

Rezolute initiates phase Ib study of RZ-402 for DME

Goldfinch Bio initiates dosing in extension study of GFB-887 for patients with FSGS

Recombinant human NAGLU coexpressing S1S3 phosphotransferase developed for Sanfilippo B syndrome

China's NMPA approves IND for phase I/II study of BBM-H901

Positive topline data from phase Ia/Ib trial of CB-4211

InnoCare receives NMPA clearance for phase II study of orelabrutinib in ITP

CRN-04894 shows pharmacologic proof of concept in phase I study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...